JP7495790B2 - Ｍｄｍ２－ｐ５３相互作用のイソインドリノン阻害剤およびそれを作製するためのプロセス - Google Patents

Ｍｄｍ２－ｐ５３相互作用のイソインドリノン阻害剤およびそれを作製するためのプロセス Download PDF

Info

Publication number
JP7495790B2
JP7495790B2 JP2019552594A JP2019552594A JP7495790B2 JP 7495790 B2 JP7495790 B2 JP 7495790B2 JP 2019552594 A JP2019552594 A JP 2019552594A JP 2019552594 A JP2019552594 A JP 2019552594A JP 7495790 B2 JP7495790 B2 JP 7495790B2
Authority
JP
Japan
Prior art keywords
alkyl
formula
compound
ring members
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019552594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515546A (ja
JP2020515546A5 (https=
Inventor
ハワード、スティーブン
デイビッド コンス、ベンジャミン
デニス、ジェフリー デイビッド セント
メアリー グリフィス－ジョンズ、シャーロット
ダグラス ヒスコック、スティーブン
サラ ホルヴェイ、リアン
リチャード バーンズ、アラン
クーザン、デイビッド
ルイーズ デクスター、ハンナ
フランソワ パラ、ギヨーム
ポール ワッツ、ジョン
ジュウェル、ロバート
アン ストックウェル、ジェニファー
ルイーズ ハースト、キム
アン レマソン、イザベル
ジョン ナッシュ、デイビッド
ダニエル オズボーン、ジェイムス
カリェハ プリード、ジョナス
ポール リチャーズ、ニコラス
マイケル デュマ、アーロン
クリストファー ビショップ、ブライアン
パーリー－ジョンズ、デイビッド
ピーター スコット、ジェレミー
サンダラム シャンマガム、ミーナクシ
リチャード マレンス、ピーター
チャールズ ラスバリー、デイビッド
ジェイムス ディクソン、ダレン
ジェイムス ゴーン、マシュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Therapeutics Ltd
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of JP2020515546A publication Critical patent/JP2020515546A/ja
Publication of JP2020515546A5 publication Critical patent/JP2020515546A5/ja
Application granted granted Critical
Publication of JP7495790B2 publication Critical patent/JP7495790B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019552594A 2017-03-28 2018-03-28 Ｍｄｍ２－ｐ５３相互作用のイソインドリノン阻害剤およびそれを作製するためのプロセス Active JP7495790B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1704965.1 2017-03-28
GBGB1704965.1A GB201704965D0 (en) 2017-03-28 2017-03-28 Pharmaceutical compounds
PCT/GB2018/050845 WO2018178691A1 (en) 2017-03-28 2018-03-28 Isoindolinone inhibitors of the mdm2-p53 interaction and process for making them

Publications (3)

Publication Number Publication Date
JP2020515546A JP2020515546A (ja) 2020-05-28
JP2020515546A5 JP2020515546A5 (https=) 2021-05-13
JP7495790B2 true JP7495790B2 (ja) 2024-06-05

Family

ID=58687834

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019552594A Active JP7495790B2 (ja) 2017-03-28 2018-03-28 Ｍｄｍ２－ｐ５３相互作用のイソインドリノン阻害剤およびそれを作製するためのプロセス

Country Status (7)

Country Link
US (3) US11603367B2 (https=)
EP (1) EP3601272A1 (https=)
JP (1) JP7495790B2 (https=)
KR (1) KR102673967B1 (https=)
CN (1) CN110678462B (https=)
GB (1) GB201704965D0 (https=)
WO (1) WO2018178691A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) * 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CN113453678A (zh) * 2018-11-26 2021-09-28 德彪药业国际股份公司 Hiv感染的联合治疗
CN109897069B (zh) * 2019-02-12 2021-08-20 华东师范大学 一种3，3-二取代吲哚啉酮及其衍生物及其合成方法和应用
CN110845288B (zh) * 2019-11-28 2022-07-19 浙江工业大学 一种手性β-氨基醛类化合物的不对称合成方法
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CN111057128B (zh) * 2019-12-25 2023-05-16 哈尔滨师范大学 一种含硫的异吲哚酮并环肽衍生物及其制备方法
CA3181715A1 (en) 2020-08-27 2022-03-03 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
GB202103080D0 (en) * 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
WO2025104679A1 (en) * 2023-11-16 2025-05-22 Otsuka Pharmaceutical Co., Ltd. Processes for making intermediates for isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004217591A (ja) 2003-01-16 2004-08-05 Dai Ichi Seiyaku Co Ltd シス選択的フルオロシクロプロパン誘導体の製造方法
US20060264473A1 (en) 2005-05-02 2006-11-23 Vladimir Khazak Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer
JP2011525897A (ja) 2008-06-25 2011-09-29 カンサー リサーチ テクノロジー リミテッド 新しい治療用作用物質
JP2011526260A (ja) 2008-07-03 2011-10-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ピロロピリジニルピリミジン−２−イルアミン誘導体

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH374071A (de) 1959-04-30 1963-12-31 Geigy Ag J R Verfahren zur Herstellung von neuen Isoindolinderivaten
US3466298A (en) 1967-03-14 1969-09-09 American Home Prod Process for the preparation of 2-(2-aminoethyl)isoindolines
US3763178A (en) 1968-09-05 1973-10-02 American Home Prod Imidazolinyl phenyl carbonyl acid addition salts and related compounds
GB1325065A (en) 1970-02-12 1973-08-01 American Home Prod Imidazoline derivatives
AR203991A1 (es) 1972-03-16 1975-11-12 Rhone Poulenc Sa Procedimiento para preparar derivados de(hidroxi-2-amino-3-propoxi)-3-isoindolinona-1
FR2217000B1 (https=) 1973-02-08 1976-04-09 Rhone Poulenc Ind
GB1601701A (en) 1977-07-22 1981-11-04 Delmar Chem Production of heterocyclic benzamide compounds
US4200759A (en) 1978-07-20 1980-04-29 Delmar Chemicals, Limited Preparation of imidazo[2,1-a]isoindole compounds
US4244966A (en) 1979-09-24 1981-01-13 American Home Products Corporation 1,3-Dihydro-3-(2-hydroxy-, 2-bromo- or 2-chloroethyl)-2H-isoindol-1-one derivatives
US4331600A (en) 1980-10-31 1982-05-25 Usv Pharmaceutical Corporation Intermediates for the synthesis of phthalimidines
US4312809A (en) 1980-10-31 1982-01-26 E. R. Squibb & Sons, Inc. Lactam derivatives of mercaptoacylamino acids
FR2533563A1 (fr) 1982-09-23 1984-03-30 Adir Nouveaux derives de la sulfonyluree, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
HU212435B (en) 1990-06-07 1996-06-28 Sandoz Ag Herbicidal compositions containing substituted phthalides and heterocyclic phthalides as active ingredient and process for preparation of their active ingredients.
TW448172B (en) 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
DE19807423A1 (de) 1998-02-21 1999-08-26 Hoechst Marion Roussel De Gmbh Subustituierte Isoindolone, ihre Herstellung und ihre Verwendung in Arzneimitteln
US6958333B1 (en) 1999-07-26 2005-10-25 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
WO2001032928A2 (en) 1999-11-05 2001-05-10 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
DE10134482A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte Isoindole und ihre Verwendung
BR0215157A (pt) 2001-12-18 2004-10-19 Hoffmann La Roche Cis-2,4,5-trifenil-imidazolinas e seu uso no tratamento de tumores
FR2840302B1 (fr) 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
EP1566378B1 (en) 2002-11-26 2012-08-15 Maruishi Pharmaceutical Co., Ltd. Isoindoline derivative
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
JP2005255660A (ja) 2004-03-10 2005-09-22 Katsuhiko Tomooka 多官能基を有するラクタム類とその製法
JPWO2005095341A1 (ja) 2004-03-30 2007-08-16 協和醗酵工業株式会社 含窒素複素環化合物
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
KR100944301B1 (ko) 2005-02-22 2010-02-24 더 리젠츠 오브 더 유니버시티 오브 미시간 Ｍｄｍ２의 소분자 억제제 및 이의 용도
CN101309905A (zh) 2005-08-12 2008-11-19 阿斯利康(瑞典)有限公司 取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
JPWO2008047831A1 (ja) 2006-10-17 2010-02-25 協和発酵キリン株式会社 Ｊａｋ阻害剤
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
SG185285A1 (en) 2007-06-03 2012-11-29 Univ Vanderbilt Benzamide mglur5 positive allosteric modulators and methods of making and using same
AU2009294673B2 (en) 2008-09-18 2014-08-14 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
KR20120099462A (ko) 2009-11-12 2012-09-10 더 리젠츠 오브 더 유니버시티 오브 미시건 스피로-옥신돌 ｍｄｍ2 길항제
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
AU2012226890B2 (en) 2011-03-10 2016-10-06 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivative
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
WO2012175520A1 (en) 2011-06-20 2012-12-27 Novartis Ag Hydroxy substituted isoquinolinone derivatives
EP2750768B1 (en) 2011-08-30 2018-10-03 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
KR101401705B1 (ko) 2012-01-31 2014-06-27 울산대학교 산학협력단 로듐 촉매를 이용한 이소인돌린 유도체의 합성방법
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
PT2914254T (pt) 2012-10-30 2020-04-02 Mei Pharma Inc Terapias de combinação para tratar cancros quimiorresistentes
SI2961388T1 (sl) 2013-03-01 2019-10-30 Astex Pharmaceuticals Inc Kombinacije zdravil
BR112015031542A2 (pt) 2013-07-03 2017-07-25 Hoffmann La Roche métodos de previsão de reação de pacientes com câncer, método de tratamento de câncer, kit de previsão da reação ao tratamento e processos, métodos e usos inovadores
US20160333419A1 (en) 2014-01-14 2016-11-17 Daiichi Sankyo Company, Limited Gene signatures associated with sensitivity to mdm2 inhibitors
ES2712973T3 (es) 2014-04-17 2019-05-17 Univ Michigan Regents Inhibidores de MDM2 y métodos terapéuticos que usan los mismos
JP2017532959A (ja) 2014-10-09 2017-11-09 第一三共株式会社 Ｍｄｍ２阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム
WO2016059241A2 (en) 2014-10-17 2016-04-21 Biomirna Holdings Ltd. Lung cancer diagnostics and therapeutics with mir-660
AU2016287585B2 (en) 2015-07-02 2020-12-17 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
EP3365334B1 (en) 2015-10-21 2024-07-17 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CA3050645A1 (en) 2018-07-27 2020-01-27 Ottawa Hospital Research Institute Treatment of acute myeloid leukemia
TWI772753B (zh) 2019-02-24 2022-08-01 大陸商蘇州亞盛藥業有限公司 Mdm2抑制劑的治療方法和生物標記物
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CA3181715A1 (en) 2020-08-27 2022-03-03 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004217591A (ja) 2003-01-16 2004-08-05 Dai Ichi Seiyaku Co Ltd シス選択的フルオロシクロプロパン誘導体の製造方法
US20060264473A1 (en) 2005-05-02 2006-11-23 Vladimir Khazak Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer
JP2011525897A (ja) 2008-06-25 2011-09-29 カンサー リサーチ テクノロジー リミテッド 新しい治療用作用物質
JP2011526260A (ja) 2008-07-03 2011-10-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ピロロピリジニルピリミジン−２−イルアミン誘導体

Also Published As

Publication number Publication date
US12077526B2 (en) 2024-09-03
JP2020515546A (ja) 2020-05-28
CN110678462A (zh) 2020-01-10
KR102673967B1 (ko) 2024-06-12
CN110678462B (zh) 2024-10-29
US11603367B2 (en) 2023-03-14
WO2018178691A1 (en) 2018-10-04
US20210101887A1 (en) 2021-04-08
EP3601272A1 (en) 2020-02-05
KR20190133190A (ko) 2019-12-02
GB201704965D0 (en) 2017-05-10
US20250074900A1 (en) 2025-03-06
US20230278989A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
JP7566806B2 (ja) 抗がん活性を有するｍｄｍ２－ｐ５３相互作用のイソインドリノン阻害剤
JP7495790B2 (ja) Ｍｄｍ２－ｐ５３相互作用のイソインドリノン阻害剤およびそれを作製するためのプロセス
KR102743663B1 (ko) 항암 활성을 갖는 mdm2-p53 상호작용의 아이소인돌리논 저해제
HK40082646A (en) Intermediates of isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
RU2794333C1 (ru) Изоиндолиноновые ингибиторы взаимодействия mdm2-p53, обладающие противораковой активностью
HK40088238A (zh) 具有抗癌活性的mdm2-p53相互作用的异吲哚啉酮抑制剂
RU2797295C1 (ru) Изоиндолиноновые ингибиторы взаимодействия mdm2-p53, обладающие противораковой активностью
HK1250715B (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210329

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240524

R150 Certificate of patent or registration of utility model

Ref document number: 7495790

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150